Correlation Between Virpax Pharmaceuticals and Living Cell

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Living Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Living Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virpax Pharmaceuticals and Living Cell Technologies, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Living Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Living Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Living Cell.

Diversification Opportunities for Virpax Pharmaceuticals and Living Cell

0.17
  Correlation Coefficient

Average diversification

The 3 months correlation between Virpax and Living is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Living Cell Technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Living Cell Technologies and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Living Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Living Cell Technologies has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Living Cell go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and Living Cell

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to under-perform the Living Cell. But the stock apears to be less risky and, when comparing its historical volatility, Virpax Pharmaceuticals is 4.75 times less risky than Living Cell. The stock trades about -0.02 of its potential returns per unit of risk. The Living Cell Technologies is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  0.84  in Living Cell Technologies on October 21, 2024 and sell it today you would lose (0.68) from holding Living Cell Technologies or give up 80.95% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy99.43%
ValuesDaily Returns

Virpax Pharmaceuticals  vs.  Living Cell Technologies

 Performance 
       Timeline  
Virpax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Living Cell Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Living Cell Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Virpax Pharmaceuticals and Living Cell Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virpax Pharmaceuticals and Living Cell

The main advantage of trading using opposite Virpax Pharmaceuticals and Living Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Living Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Living Cell will offset losses from the drop in Living Cell's long position.
The idea behind Virpax Pharmaceuticals and Living Cell Technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio